ArticleScientific reports2025
Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The development of the immune system (ISD) plays a pivotal role in both the genesis and progression of tumors, yet its specific functions in hepatocellular carcinoma (HCC) and the mechanisms behind sorafenib resistance remain elusive. In our investigation, we initially created 167 algorithms by amalgamating 10 distinct machine learning algorithms to identify an optimal and potent ISD-related signature (ISDRS), which proved to be superior to 73 previously published signatures. Moreover, we found that resistance to sorafenib was associated with both ISD levels and ISDRS. These, in turn, exhibited a positive correlation with the infiltration of T regulatory cells (Tregs) and a negative correlation with the levels of IL-6/IL-6R. Furthermore, through single-cell analysis, we uncovered a novel Tregs subgroup that contributes to sorafenib resistance and identified BATF as a potential biomarker for this subgroup.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.